Octreotide

Classification

Somatostatin analogue

Approval status

Approved medicine

Research status

Labelled indications are defined in product information.

Molecular formula

Insufficient reliable evidence identified.

Molecular weight

Insufficient reliable evidence identified.

Sequence

Cyclic octapeptide somatostatin analogue.

Primary biological target

Somatostatin receptors (sst2/sst5 predominant)

Half-life

Insufficient reliable evidence identified.

Routes investigated

Subcutaneous, Intramuscular depot, Intravenous

Human evidence level

A — Approved clinical use / strong human evidence

A synthetic analogue of somatostatin used as a prescription medicine for hormone-secreting tumours and related labelled indications.

Established (labelled / textbook receptor pharmacology)

Agonist at somatostatin receptors (notably sst2/sst5), suppressing GH, glucagon, insulin and various GI peptides depending on tissue.

Reduces pathological hormone secretion in labelled neuroendocrine and acromegaly settings as described in product information.

• Acromegaly
• Neuroendocrine tumours
• Variceal bleeding (product-specific)

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Overall human evidence grade: A · Approved clinical use / strong human evidence

Extensive labelled clinical use; see PI and oncology/endocrinology guidelines.

Animal, cell and in-vitro findings are listed separately from human effects.

Somatostatin receptor pharmacology is well characterised.

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

GI symptoms, gallstones, glucose dysregulation, injection-site reactions — see PI.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. See product information (hypersensitivity; caution in diabetes and biliary disease).

Approved prescription medicine, brand- and indication-specific (FDA/EMA).

ARTG-registered presentations exist; verify current PI. Not sold by Cellular Sequence.

1. [1] Octreotide prescribing information

   Octreotide prescribing information

   Open source